Spots Global Cancer Trial Database for advanced disease
Every month we try and update this database with for advanced disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | NCT02131506 | HER-2 Positive ... Malignant Neopl... | Lapatinib, Cael... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Second Line Therapy in Advanced Biliary Tract Cancer | NCT01530503 | Biliary Tract C... | capecitabine an... Capecitabine | 18 Years - 75 Years | IRCCS San Raffaele | |
| IMCgp100 in Advanced Unresectable Melanoma | NCT01209676 | Melanoma Advanced Diseas... Unresectable | IMCgp100 inject... | 18 Years - | University of Pennsylvania | |
| Second Line Therapy in Advanced Biliary Tract Cancer | NCT01530503 | Biliary Tract C... | capecitabine an... Capecitabine | 18 Years - 75 Years | IRCCS San Raffaele | |
| A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo | NCT02496832 | Pancreatic Aden... Advanced Diseas... Metastatic Dise... | 18F-Fluoroazomy... | 18 Years - | University Health Network, Toronto | |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer | NCT00212615 | C04.588.274.476... | Oxaliplatin (El... Capecitabine (X... | 18 Years - | Odense University Hospital | |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | NCT03546426 | Mesothelioma, M... PD-L1 Negative Advanced Cancer Progressive Dis... | Pembrolizumab Autologous dend... Interleukin-2 | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | NCT01854034 | Non Small Cell ... | AUY922 | 18 Years - | Massachusetts General Hospital | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | NCT02131506 | HER-2 Positive ... Malignant Neopl... | Lapatinib, Cael... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer | NCT01853813 | Colorectal Canc... | Bevacizumab and... | 18 Years - 75 Years | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | |
| Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors | NCT02538432 | Prostate Cancer Non-Small Cell ... Breast Cancer | RQ-00000007 Gemcitabine | 18 Years - | University of Maryland, Baltimore | |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | NCT03546426 | Mesothelioma, M... PD-L1 Negative Advanced Cancer Progressive Dis... | Pembrolizumab Autologous dend... Interleukin-2 | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | NCT01484860 | Adenocarcinoma ... Metastatic Dise... | AUY922 | 18 Years - | University Health Network, Toronto | |
| Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | NCT00741988 | Non-Small Cell ... | Ixabepilone Carboplatin Bevacizumab | 18 Years - | SCRI Development Innovations, LLC | |
| First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer | NCT01853813 | Colorectal Canc... | Bevacizumab and... | 18 Years - 75 Years | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
